RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 401–500 of 1,003
Pinilla-Macua, I., Watkins, S. C., & Sorkin, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520301113 · Cited by 59
Endometrial Carcinoma: Specific Targeted Pathways
Eritja, N., Yeramian, A., Chen, B., Llobet‐Navàs, D., Ortega, E., Colás, E., Abal, M., Dolcet, X., Reventós, J., & Matías‐Guiu, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_6 · Cited by 64
New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 63
KRAS induces lung tumorigenesis through microRNAs modulation
Shi, L., Middleton, J. D., Jeon, Y.-J., Magee, P., Veneziano, D., Laganà, A., Leong, H. S., Sahoo, S., Fassan, M., Booton, R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0243-9 · Cited by 60
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
Ling, Y., Liu, J., Qian, J., Meng, C., Guo, J., Gao, W., Xiong, B., Ling, C., & Zhang, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102115720 · Cited by 59
Rit subfamily small GTPases: Regulators in neuronal differentiation and survival
Shi, G., Cai, W., & Andres, D. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.002 · Cited by 61
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2
Donninger, H., Calvisi, D. F., Barnoud, T., Clark, J., Schmidt, M., Vos, M. D., & Clark, G. J. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201408087 · Cited by 60
Leung, E. L., Luo, L. X., Liu, Z. Q., Wong, V. K. W., Lu, L., Xie, Y., Zhang, N., Qu, Y. Q., Fan, X., Li, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0065-9 · Cited by 60
Sabir, F., Qindeel, M., Zeeshan, M., Ain, Q. U., Rahdar, A., Barani, M., González, E., & Aboudzadeh, M. A. (2021) · Processes · doi:10.3390/pr9040621 · Cited by 63
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 62
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
Ni, R., Li, Z., Li, L., Peng, D., Ming, Y., Li, L., & Liu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1143798 · Cited by 66
Proliferation and tissue remodeling in cancer: the hallmarks revisited
Markert, E. K., Levine, A. J., & Vázquez, A. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.140 · Cited by 62
“Ras activation has been commonly associated with increased proliferation.(18) More recently, it has been shown that Kras oncogenic mutations activate glycosylation,(19) which is known to have a key role in invasion and angiogenesis.”
BackgroundGraded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
Augsten, M., Böttcher, A., Spanbroek, R., Rubio, I., & Friedrich, K. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-1 · Cited by 57
“Ras proteins play important roles in receptor-mediated signal transduction pathways that control cell proliferation and differentiation and are moreover critically involved in the regulation of cell motility and invasiveness [3,6,7].”
BackgroundPigs as models of human cancers
Flisikowska, T., Kind, A., & Schnieke, A. (2016) · Theriogenology · doi:10.1016/j.theriogenology.2016.04.058 · Cited by 60
Ye, H., Zhang, C., Wang, B.-J., Tan, X.-H., Zhang, W.-P., Teng, Y., & Yang, X. Y. (2013) · Oncogene · doi:10.1038/onc.2013.468 · Cited by 58
The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors
Rasheed, S. A. K., Subramanyan, L. V., Lim, W. K., Udayappan, U. K., Wang, M., & Casey, P. J. (2021) · Oncogene · doi:10.1038/s41388-021-02069-w · Cited by 61
“For example, the most commonly found oncogene, mutant RAS, and tumor suppressor, p53, have been linked to all hallmarks of cancer, including emerging hallmarks [36, 37].”
BackgroundFujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., & McCormick, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1623 · Cited by 55
“K-Ras mutations are frequently found in pancreatic, lung and colorectal tumors [1-3].”
BackgroundAli, S. S., Banerjee, S., Logna, F., Bao, B., Philip, P. A., Korc, M., & Sarkar, F. H. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.24036 · Cited by 56
“…mutations are frequently found in PC, and occurs during early stages of tumor initiation (Kim et al., 2011; Krantz et al., 2011;Mohri et al., 2011; Ray et al., 2011) which is believed to arise through the progression of low grade to high-grade pancreatic intraepithelial neoplasia (Pan1N) (Hruban…”
BackgroundRetractedStructure-based inhibition of protein–protein interactions
Watkins, A. M., & Arora, P. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.047 · Cited by 64
Screening cell mechanotype by parallel microfiltration
Qi, D., Gill, N. K., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., Taylor‐Harding, B., Wiedemeyer, W. R., & Rowat, A. C. (2015) · Scientific Reports · doi:10.1038/srep17595 · Cited by 56
Jia, Y., Jiang, T., Li, X., Zhao, C., Zhang, L., Zhao, S., Liu, X., Qiao, M., Luo, J., Shi, J., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7016 · Cited by 60
“Point mutations occurred in tumors result in the loss of intrinsic GTPase activity and consequently in the deregulation of cell proliferation signals (13,14).”
WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation
Jeong, W.-J., Park, J., Kim, W.-S., Ro, E. J., Jeon, S. H., Lee, S., Park, Y. N., Min, D. S., & Choi, K. (2019) · Nature Communications · doi:10.1038/s41467-018-08230-6 · Cited by 56
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 57
Charitou, T., Srihari, S., Lynn, M. A., Jarboui, M. A., Fasterius, E., Moldovan, M. V., Shirasawa, S., Tsunoda, T., Ueffing, M., Xie, J., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0477-7 · Cited by 61
Yao, Z., Aboualizadeh, F., Kroll, J. R., Akula, I., Snider, J. D., Lyakisheva, A., Tang, P. W., Kotlyar, M., Jurišica, I., Boxem, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16299-1 · Cited by 63
Post-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 59
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103592118 · Cited by 58
Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Alam, M., Hasan, G. M., Eldin, S. M., Adnan, M., Riaz, M. B., Islam, A., Khan, I., & Hassan, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114452 · Cited by 56
Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
Stopa, K. B., Kusiak, A. A., Szopa, M. D., Ferdek, P. E., & Jakubowska, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093218 · Cited by 59
Galanina, N., Bejar, R. L., Choi, M. Y., Goodman, A. M., Wieduwilt, M. J., Mulroney, C. M., Kim, L., Yeerna, H., Tamayo, P., Vergilio, J., et al. (2018) · Cancers · doi:10.3390/cancers11010011 · Cited by 55
El-Jawhari, J. J., El-Sherbiny, Y. M., Scott, G. B., Morgan, R. S. M., Prestwich, R., Bowles, P. A., Blair, G. E., Tanaka, T., Rabbitts, T. H., Meade, J. L., et al. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.020 · Cited by 54
Cancer Clocks Out for Lunch: Disruption of Circadian Rhythm and Metabolic Oscillation in Cancer
Altman, B. J. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00062 · Cited by 57
“Oncogenic RAS is known to promote transformation and altered cell metabolism (Pylayeva-Gupta et al., 2011; Kimmelman, 2015), and work spanning decades suggests that wild-type RAS is both influenced by and influences the circadian clock, and thus, mutated oncogenic RAS may potentially alter…”
BackgroundDietrich, P., Kuphal, S., Spruß, T., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncogene · doi:10.1038/onc.2017.391 · Cited by 59
Signal transduction pathways and resistance to targeted therapies in glioma
Tomiyama, A., & Ichimura, K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.004 · Cited by 56
Sharma, S. B., Lin, C., Farrugia, M. K., McLaughlin, S. L., Ellis, E. J., Brundage, K. M., Salkeni, M. A., & Ruppert, J. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00480-14 · Cited by 63
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Norton, C., Shaw, M. S., Rubnitz, Z., Smith, J. L., Soares, H. P., Nevala-Plagemann, C., Garrido‐Laguna, I., & Florou, V. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.53588 · Cited by 57
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 59
Nohara, K., Tateishi, Y., Suzuki, T., Okamura, K., Murai, H., Takumi, S., Maekawa, F., Nishimura, N., Kobori, M., & Ito, T. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs203 · Cited by 53
RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis
Huang, Y.-T., Zhao, M., Xu, H., Wang, K., Fu, Z., Jiang, Y., & Yao, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2244 · Cited by 56
“RAS mutations are very common, being found in a broad spectrum of malignant diseases[13].”
BackgroundWang, J.-Y., Wu, P.-K., Chen, P. C.-H., Lee, C.-W., Chen, W.-M., & Hung, S.-C. (2017) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0226 · Cited by 49
Klingbeil, O., Lesche, R., Gelato, K. A., Haendler, B., & Lejeune, P. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.271 · Cited by 55
“About 80% of lung cancers can be histologically classified as non-small cell lung cancers (NSCLC),(18) of which 30% harbor an activating oncogenic mutation in the GTPase domain of the KRAS signaling protein.(19) Co-occurring genetic alterations of KRAS and the Liver kinase B1 (LKB1) tumor suppressor gene that lead to…”
BackgroundEpithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Matrone, A., Gambale, C., Prete, A., & Elisei, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.864253 · Cited by 58
Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
Grabocka, E., Commisso, C., & Bar‐Sagi, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0650 · Cited by 56
Self-citationREDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors
Qiao, S., Koh, S., Vivekanandan, V., Salunke, D., Patra, K. C., Zaganjor, E., Ross, K. N., Mizukami, Y., Jeanfavre, S., Chen, A. L., et al. (2020) · Genes & Development · doi:10.1101/gad.335166.119 · Cited by 54
Ye, W.-L., Huang, L., Yang, X., Wan, S., Gan, W.-J., Yang, Y., He, X., Liu, F., Guo, X., Liu, Y.-X., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406936121 · Cited by 54
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
Filis, P., Salgkamis, D., Matikas, A., & Zerdes, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104250 · Cited by 55
BCL-XL directly modulates RAS signalling to favour cancer cell stemness
Trécesson, S. D. C., Souazé, F., Basseville, A., Bernard, A.-C., Pécot, J., Lopez, J., Bessou, M., Sarosiek, K. A., Letai, A. G., Barillé‐Nion, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01079-1 · Cited by 54
“Activation of RAS and its downstream pathways MAPK/ERK and PI3K/AKT have well documented anti-apoptotic consequences due to the induction of anti-apoptotic proteins expression and the down-regulation or inactivation of pro-apoptotic effectors 7 .”
BackgroundGenomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy
Necchi, A., Bratslavsky, G., Corona, R. J., Chung, J. H., Millis, S. Z., Elvin, J. A., Vergilio, J.-A., Suh, J., Ramkissoon, S., Severson, E., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2018.07.013 · Cited by 52
Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
Okuhira, K., Shoda, T., Omura, R., Ohoka, N., Hattori, T., Shibata, N., Demizu, Y., Sugihara, R., Ichino, A., Kawahara, H., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105569 · Cited by 52
“Mutations that promote the expression or activity of specific proteins often drive the excessive cell proliferation associated with various diseases such as cancer (Muller and Vousden, 2013; Pylayeva-Gupta et al., 2011).”
BackgroundA thirty-year quest for a role of R-Ras in cancer: from an oncogene to a multitasking GTPase
Liu, W. N., Yan, M., & Chan, A. M.-L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.003 · Cited by 53
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
Lu, J., Bera, A. K., Gondi, S., & Westover, K. D. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00974 · Cited by 51
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
Sikdar, N., Saha, G., Dutta, A., Ghosh, S., Shrikhande, S. V., & Banerjee, S. (2018) · Current Genomics · doi:10.2174/1389202919666180221160753 · Cited by 56
Burns, M. C., Howes, J. E., Sun, Q., Little, A. J., Camper, D. V., Abbott, J. R., Phan, J., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.01.025 · Cited by 47
“Once activated, mutant RAS promotes oncogenesis by endowing cells with the ability to proliferate, resist apoptosis, alter metabolism, evade the immune system, invade surrounding tissues, and metastasize to distant sites [3].”
BackgroundGrifoni, D., Sollazzo, M., Fontana, E., Froldi, F., & Pession, A. (2015) · Scientific Reports · doi:10.1038/srep09061 · Cited by 53
Tumor suppressor role of phospholipase Cε in Ras-triggered cancers
Martins, M., McCarthy, A., Baxendale, R., Guichard, S., Magno, L., Kessaris, N., El-Bahrawy, M., Yu, P., & Katan, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311500111 · Cited by 51
“A mutations in the Ras subfamily of small GTPases contribute to the formation of a large proportion of human tumors (1).”
BackgroundDiet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis
Ramadori, G., Konstantinidou, G., Venkateswaran, N., Biscotti, T., Morlock, L., Galiè, M., Williams, N. S., Luchetti, M. M., Santinelli, A., Scaglioni, P. P., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.11.020 · Cited by 54
“Activating mutations of the protooncogene KRAS (mutantKRAS) occur in 30%of NSCLC cases (Pylayeva-Gupta et al., 2011).”
BackgroundWu, J., Sun, Y., Zhang, P.-Y., Qian, M., Zhang, H., Chen, X., Ma, D., Xu, Y., Chen, X., & Tang, K. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.289 · Cited by 54
“Mutations in Ras family genes (H-Ras, K-Ras and N-Ras) have been detected in ~ 30% of human cancers.(16,17) Ras activation leads to the membrane recruit-”
BackgroundManent, J., Banerjee, S., Simoes, R. D. M., Zoranovic, T., Mitsiades, C. S., Penninger, J. M., Simpson, K. J., Humbert, P. O., & Richardson, H. E. (2017) · Oncogene · doi:10.1038/onc.2017.175 · Cited by 53
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 51
Research progress on KRAS mutations in colorectal cancer
Cefalì, M., Epistolio, S., Palmarocchi, M. C., Frattini, M., & Dosso, S. D. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.61 · Cited by 63
Ali, E. S., Akter, S., Ramproshad, S., Mondal, B., Riaz, T. A., Islam, M. T., Khan, I. N., Docea, A. O., Călina, D. C., Sharifi‐Rad, J., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02666-z · Cited by 53
“• Alteration of the components of cytoplasmic signaling pathways, which produce a flow of mitogenic signaling without their stimulation by receptors; for example, the mitogen-activated protein kinase pathway, which consists of RAS → RAF → MEK → M APK → ERK → FOS proteins, plays a central role in about 25% of human can…”
BackgroundGrade, M., Wolff, H. A., Gaedcke, J., & Ghadimi, Β. M. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0929-5 · Cited by 54
“The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), a member of a large family of GTP-binding proteins involved in signal transduction [53, 54], plays an important role in colorectal carcinogenesis because a high percentage of colorectal carcinomas are characterized by activating mutations of this oncogen…”
BackgroundRole of RAS signaling in ovarian cancer
Therachiyil, L., Anand, A., Azmi, A., Bhat, A. A., Korashy, H. M., & Shahab Uddin, M. S. (2022) · F1000Research · doi:10.12688/f1000research.126337.1 · Cited by 54
USP7 deubiquitinates KRAS and promotes non-small cell lung cancer
Huang, B., Cao, D., Yuan, X., Xiong, Y., Chen, B., Wang, Y., Niu, X., Tian, R., & Huang, H. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114917 · Cited by 54
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 53
Chen, X., Makarewicz, J. M., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2014) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 46
“KRAS mutations predominate in pancreas, lung, and colorectal malignancies, whereas NRAS mutations are found in melanomas and hematopoietic tumors (1, 2).”
BackgroundLiu, Y., Sànchez‐Tilló, E., Lu, X., Huang, L. F., Clem, B. F., Telang, S., Jenson, A. B., Cuatrecasas, M., Chesney, J. A., Postigo, A. A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.533505 · Cited by 53
“Activating mutations in the Ras pathway are frequent in cancer, leading to the short-circuiting of growth factor signaling required for cancer cell proliferation and survival as tumors initiate in growth factor-deficient environments (1, 2).”
BackgroundRas Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 54
Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
Kießling, M. K., Schuierer, S., Stertz, S., Beibel, M., Bergling, S., Knehr, J., Carbone, W., de Vallière, C., Tchinda, J., Bouwmeester, T., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-3042-2 · Cited by 50
“Similarly , EGFR was depleted in the HCC-827 cell line but not in the NRAS mutant CHP-212 cell line (Additional file 1: Figure S4h).”
BackgroundInfluentialChen, J., Wang, L., Wang, W., Sun, H., Pang, L., & Bao, H. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104639 · Cited by 49
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 51
“It is now wholly understood that KRAS oncogenic mutations facilitate autocrine signaling and interactions with the TME, specifically by immune response evasion and eventually resulting in cancer development, invasion, and progression [13,14].”
Disrupted molecular glue complex drives RAS inhibitor resistance
Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 53
Changing mutational and adaptive landscapes and the genesis of cancer
Liggett, L. A., & DeGregori, J. V. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.005 · Cited by 55
“If we consider the characteristic genetic changes in cancer independently, their benefit to a cell becomes more challenging to explain [9].”
InfluentialAn essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
Shankar, S., Tien, J. C.-Y., Siebenaler, R. F., Chugh, S., Dommeti, V. L., Zelenka-Wang, S., Waninger, J. J., Juckette, K. M., Xu, A., Wang, X.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16309-2 · Cited by 51
Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity
Adhikari, H., Kattan, W. E., Kumar, S., Zhou, P., Hancock, J. F., & Counter, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-25523-5 · Cited by 52
The role of KRAS splice variants in cancer biology
Nuevo‐Tapioles, C., & Philips, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1033348 · Cited by 48
“RAS-mediated signaling drives tumor onset, maintenance and progression not only by deregulating tumor-autonomous cellular growth control and altering the tumor microenvironment (Pylayeva-Gupta et al., 2011; Simanshu et al., 2017; Hamarsheh et al., 2020), but also by rewiring”
BackgroundWhat makes oncogenes mutually exclusive?
Cisowski, J., & Bergö, M. O. (2016) · Small GTPases · doi:10.1080/21541248.2016.1212689 · Cited by 51
Mellema, W. W., Dingemans, A. C., Thunnissen, E., Snijders, P. J. F., Derks, J. L., Heideman, D. A. M., van Suylen, R. J., & Smit, E. F. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318298764e · Cited by 50
Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase)
Ilinskaya, O. N., Singh, I., Владимировна, Д. Е., Владимировна, У. В., Kayumov, A. R., & Barreto, G. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.005 · Cited by 47
Britannin induces apoptosis through AKT-FOXO1 pathway in human pancreatic cancer cells
Moeinifard, M., Hassan, Z. M., Fallahian, F., Moghadam, M. H., & Taghikhani, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.025 · Cited by 47
Cheng, T.-M., Chu, H., Lee, Y.-C., Wang, D., Chang, C., Chung, K.-L., Yen, H., Hsiao, C.-W., Pan, X.-Y., Kuo, T., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04961 · Cited by 49
HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer
Sugita, S., Enokida, H., Yoshino, H., Miyamoto, K., Yonemori, M., Sakaguchi, T., Osako, Y., & Nakagawa, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4435 · Cited by 49
“…encode three closely related RAS proteins, HRas proto-oncogene GTPase (HRAS), NRAS proto-oncogene GTPase (NRAS) and KRAS proto-oncogene GTPase (KRAS), which have critical roles in fundamental cellular processes, including proliferation, survival, differentiation, motility and transcription (5).”
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., López-Beltrán, A., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Cheng, L. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 52
“11 Although RAS proteins interact with several effectors, the two major signalling pathways through which RAS proteins exert their function are mitogen-activated protein kinase (MAPK) and phospho-inositide-3 kinase (PI3K).”
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Zhu, C., Zhuang, W., Chen, L., Yang, W., & Ou, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.09 · Cited by 50
“KRAS mutations account for 90% of RAS mutations found in lung adenocarcinoma (16).”
BackgroundTjomsland, V., Bojmar, L., Sandström, P., Bratthäll, C., Messmer, D., Spångeus, A., & Larsson, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070874 · Cited by 45
“Inflammation is strongly connected to most types of cancer and involve activation of oncogenes and/or inactivation of tumor suppressor genes that influence the proinflammatory transcriptional programs by the malignant cells [10].”
BackgroundInfluentialRas signaling is essential for skin development
Drosten, M., Lechuga, C. G., & Barbacid, M. (2014) · Oncogene · doi:10.1038/onc.2013.254 · Cited by 46
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
“KRAS is also frequently mutated in other tumor types, including pancreatic (>90%) and colon (∼30%) cancer (2).”
BackgroundGenomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Scharpf, R. B., Balan, A., Ricciuti, B., Fiksel, J., Cherry, C., Wang, C., Lenoue-Newton, M. L., Rizvi, H. A., White, J. R., Baras, A. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1731 · Cited by 49
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S. M., Bettini, A., Longo, F., Moscetti, L. I., Ganzinelli, M., Lauricella, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv318 · Cited by 48
“be involved in multiple processes during lung carcinogenesis, tumor growth and metastatic spread [1].”
BackgroundKRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
“The GTPases cycle between a GTP-bound ‘on’ state and a GDP-bound ‘off’ state [16,17].”
Peng, H., Li, T. W. H., Yang, H., Moyer, M. P., Mato, J. M., & Lu, S. C.-L. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.12.016 · Cited by 46
Jardim, D. L. F., Conley, A. P., & Subbiah, V. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-112 · Cited by 46
“Activation of this protein causes cell growth, differentiation, and survival mainly through the RAF/MAPK/ERK pathway [23].”
BackgroundPeroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells
Kwon, T., Bak, Y., Park, Y., Jang, G.-B., Nam, J., Yoo, J. E., Park, Y. N., Bak, I. S., Kim, J., Yoon, D., et al. (2016) · Stem Cells · doi:10.1002/stem.2323 · Cited by 46
KRAS Engages AGO2 to Enhance Cellular Transformation
Shankar, S., Pitchiaya, S., Malik, R., Kothari, V., Hosono, Y., Yocum, A. K., Gundlapalli, H., White, Y., Firestone, A., Cao, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.034 · Cited by 46
“Approximately one-third of human cancers harbor an oncogenic mutation in HRAS, KRAS, or NRAS (Balmain and Pragnell , 1983; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011).”
Blocking Ras inhibition as an antitumor strategy
Marín‐Ramos, N. I., Ortega‐Gutiérrez, S., & López-Rodríguez, M. L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.017 · Cited by 50
Advances in oncolytic adenovirus therapy for pancreatic cancer
Nattress, C. B., & Halldén, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.006 · Cited by 50
An Integrated Global Analysis of Compartmentalized HRAS Signaling
Santra, T., Herrero, A., Rodríguez, J., von Kriegsheim, A., Iglesias-Martinez, L. F., Schwarzl, T., Higgins, D. G., Aye, T., Heck, A. J. R., Calvo, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.038 · Cited by 49
“However, these approaches are hampered by the large number of RAS effector pathways and the intricacies of the functional interactions between them (Pylayeva-Gupta et al., 2011).”
BackgroundThe Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Arai, H., Elliott, A., Xiu, J., Wang, J., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Sohal, D. P. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3635 · Cited by 49
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.